向雌激素受体信号传递治疗心力衰竭
Chenyue Qian1, Jingjin Liu2,3,4,5,6, Huadong Liu7,8,9,10,11
1The Second Clinical Medical College, Jinan University, Shenzhen, 518020, Guangdong, China.
Heart failure reviews
|October 2, 2023
概括
绝经前妇女由于雌激素的作用,心力衰竭 (HF) 率较低.
科学领域:
- 心血管科学 心血管科学
- 内分泌学 在内分泌学.
- 妇女健康 妇女健康
背景情况:
- 心力衰竭 (HF) 是一个全球性的健康问题.
- 与绝经后的女性和男性相比,绝经前的女性表现出较低的HF发生率,发病率和死亡率.
- 雌激素被认为在绝经前妇女中提供心脏保护,但机制尚未完全理解.
研究的目的:
- 审查雌激素受体在心血管系统中的作用.
- 阐明雌激素在心力衰竭中的心脏保护作用的机制.
- 探索针对这些机制的潜在治疗策略.
主要方法:
- 对心血管系统中雌激素受体研究的文献综述.
- 对雌激素对心力衰竭病理生理学影响的研究分析.
- 对激素替代疗法和运动干预措施的临床和临床前数据的检查.
主要成果:
- 雌激素受体存在于心血管组织中.
- 雌激素信号通路与缓解心力衰竭进展有关.
- 激素替代疗法和运动显示出调节这些途径的潜力.
结论:
- 雌激素在心力衰竭中的心脏保护作用通过特定的受体通路进行介导.
- 向雌激素机制为HF预防和治疗提供了有希望的途径.
- 需要进一步的研究来优化治疗干预措施.
更多相关视频
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
454
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
454
Heart Failure II: Pathophysiology
14
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
14
Heart Failure V: Medical Management
12
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
12
Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Heart Failure Drugs: Diuretics
412
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
412
Heart Failure Drugs: β-Blockers
357
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
357


